BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32940116)

  • 1. The value of p16 and HPV DNA in non-tonsillar, non-base of tongue oropharyngeal cancer.
    Hammarstedt L; Holzhauser S; Zupancic M; Kapoulitsa F; Ursu RG; Ramqvist T; Haeggblom L; Näsman A; Dalianis T; Marklund L
    Acta Otolaryngol; 2021 Jan; 141(1):89-94. PubMed ID: 32940116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 - Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas.
    Marklund L; Holzhauser S; de Flon C; Zupancic M; Landin D; Kolev A; Haeggblom L; Munck-Wikland E; Hammarstedt-Nordenvall L; Dalianis T; Näsman A
    Eur J Cancer; 2020 Nov; 139():192-200. PubMed ID: 32951963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
    Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of cell cycle-associated proteins p16, pRB, cyclin D1 and p53 in resected oropharyngeal carcinoma.
    Plath M; Broglie MA; Förbs D; Stoeckli SJ; Jochum W
    J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):53. PubMed ID: 30189895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double positivity for HPV DNA/p16 in tonsillar and base of tongue cancer improves prognostication: Insights from a large population-based study.
    Garnaes E; Frederiksen K; Kiss K; Andersen L; Therkildsen MH; Franzmann MB; Specht L; Andersen E; Norrild B; Kjaer SK; von Buchwald C
    Int J Cancer; 2016 Dec; 139(11):2598-605. PubMed ID: 27537425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Zupancic M; Kostopoulou ON; Holzhauser S; Lukoseviciute M; Jylhä C; Marklund L; Näsman A; Sivars L; Dalianis T
    Oral Oncol; 2024 Apr; 151():106749. PubMed ID: 38461771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma.
    Kawakami H; Okamoto I; Terao K; Sakai K; Suzuki M; Ueda S; Tanaka K; Kuwata K; Morita Y; Ono K; Nishio K; Nishimura Y; Doi K; Nakagawa K
    Cancer Med; 2013 Dec; 2(6):933-41. PubMed ID: 24403267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years.
    Haeggblom L; Ramqvist T; Tommasino M; Dalianis T; Näsman A
    Papillomavirus Res; 2017 Dec; 4():1-11. PubMed ID: 29179862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
    Oguejiofor KK; Hall JS; Mani N; Douglas C; Slevin NJ; Homer J; Hall G; West CM
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):630-8. PubMed ID: 23916365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing.
    Nauta IH; Rietbergen MM; van Bokhoven AAJD; Bloemena E; Lissenberg-Witte BI; Heideman DAM; Baatenburg de Jong RJ; Brakenhoff RH; Leemans CR
    Ann Oncol; 2018 May; 29(5):1273-1279. PubMed ID: 29438466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological characteristics of HPV(+) oropharyngeal squamous cell carcinoma].
    Zhao YH; Bai YP; Mao ML; Zhang H; Zhao XL; Yang DM; Wan HF; Liu HG
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):127-131. PubMed ID: 30695865
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas.
    Wang F; Zhang H; Xue Y; Wen J; Zhou J; Yang X; Wei J
    Cancer Med; 2017 May; 6(5):910-917. PubMed ID: 28378539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas.
    Rietbergen MM; Snijders PJ; Beekzada D; Braakhuis BJ; Brink A; Heideman DA; Hesselink AT; Witte BI; Bloemena E; Baatenburg-De Jong RJ; Leemans CR; Brakenhoff RH
    Int J Cancer; 2014 May; 134(10):2366-72. PubMed ID: 24249631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Papillomavirus DNA Detection by Droplet Digital PCR in Formalin-Fixed Paraffin-Embedded Tumor Tissue from Oropharyngeal Squamous Cell Carcinoma Patients.
    Schiavetto CM; de Abreu PM; von Zeidler SV; de Jesus LM; Carvalho RS; Cirino MT; Carloni AC; Oliveira C; Scapulatempo-Neto C; de Almeida GC; de Menezes NS; Carvalho AL; Reis RM; de Carvalho AC
    Mol Diagn Ther; 2021 Jan; 25(1):59-70. PubMed ID: 33245553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status.
    Wendt M; Hammarstedt-Nordenvall L; Zupancic M; Friesland S; Landin D; Munck-Wikland E; Dalianis T; Näsman A; Marklund L
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving landscape of human papillomavirus-related oropharyngeal squamous cell carcinoma at a single institution in Northern Italy.
    Morbini P; Alberizzi P; Ferrario G; Capello G; De Silvestri A; Pedrazzoli P; Tinelli C; Benazzo M
    Acta Otorhinolaryngol Ital; 2019 Feb; 39(1):9-17. PubMed ID: 30936574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of p16
    Wagner S; Prigge ES; Wuerdemann N; Reder H; Bushnak A; Sharma SJ; Obermueller T; von Knebel Doeberitz M; Dreyer T; Gattenlöhner S; Wolf G; Pons-Kühnemann J; Wittekindt C; Klussmann JP
    Br J Cancer; 2020 Sep; 123(7):1114-1122. PubMed ID: 32624580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oropharyngeal squamous cell carcinoma: p16/p53 immunohistochemistry as a strong predictor of HPV tumour status.
    Benzerdjeb N; Tantot J; Blanchet C; Philouze P; Mekki Y; Lopez J; Devouassoux-Shisheboran M
    Histopathology; 2021 Sep; 79(3):381-390. PubMed ID: 33560536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias.
    Mooren JJ; Gültekin SE; Straetmans JM; Haesevoets A; Peutz-Kootstra CJ; Huebbers CU; Dienes HP; Wieland U; Ramaekers FC; Kremer B; Speel EJ; Klussmann JP
    Int J Cancer; 2014 May; 134(9):2108-17. PubMed ID: 24127203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.